Related references
Note: Only part of the references are listed.Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
Ulrike Klein et al.
ANNALS OF HEMATOLOGY (2011)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. -L. Harousseau et al.
ANNALS OF ONCOLOGY (2010)
Lenalidomide mode of action: linking bench and clinical findings
Faith Davies et al.
BLOOD REVIEWS (2010)
The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function
Meletios Dimopoulos et al.
CANCER (2010)
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
A. K. Gandhi et al.
CURRENT CANCER DRUG TARGETS (2010)
Recent advances of IMiDs in cancer therapy
Shirong Li et al.
CURRENT OPINION IN ONCOLOGY (2010)
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Jean-Luc Harousseau et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
Shinsuke Iida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone
H. Avet-Loiseau et al.
LEUKEMIA (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Mechanism of action of immunomodulatory agents in multiple myeloma
Thomas Reske et al.
MEDICAL ONCOLOGY (2010)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
E. Terpos et al.
ANNALS OF ONCOLOGY (2009)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
Christine Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
Edward A. Stadtmauer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
Anne-Tove Brenne et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells
Monica Bernal et al.
HUMAN IMMUNOLOGY (2009)
Newer therapeutic molecules for multiple myeloma
P Jain et al.
INDIAN JOURNAL OF CANCER (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
A. Palumbo et al.
LEUKEMIA (2009)
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
S. Colucci et al.
LEUKEMIA (2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2009)
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
M. Dimopoulos et al.
LEUKEMIA (2009)
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Jean-Luc Harousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
Michael Drummond et al.
VALUE IN HEALTH (2009)
Prognostic: factors for multiple myeloma in the era of novel agents
J. Blade et al.
ANNALS OF ONCOLOGY (2008)
The role of novel drugs in multiple myeloma
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2008)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma
Bart Burington et al.
CLINICAL CANCER RESEARCH (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
I. Breitkreutz et al.
LEUKEMIA (2008)
Pathogenesis and treatment of renal failure in multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2008)
Economic evaluation of lenolidomide use for multiple myeloma in Scotland in patients who have received one prior therapy
B. Deniz et al.
VALUE IN HEALTH (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis
Nionhang Chen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution
A. K. Stewart et al.
LEUKEMIA (2007)
Novel therapies in myeloma
Patrick J. Hayden et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Multiple myeloma: Charging toward a bright future
Jed A. Katzel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma
H. Ludwig et al.
ANNALS OF ONCOLOGY (2007)
Treatment strategies in elderly patients with multiple myeloma
Hang Quach et al.
DRUGS & AGING (2007)
Lenalidomide in myelodysplastic syndrome and multiple myeloma
Sachin R. Shah et al.
DRUGS (2007)
An update: Health economics of managing multiple myeloma
K. Moeremans et al.
EUROPEAN JOURNAL OF CANCER (2006)
Thalidomide and lenalidomide in the treatment of multiple myeloma
Shaji Kumar et al.
EUROPEAN JOURNAL OF CANCER (2006)
Bone markers in multiple myeloma
Ulrike Heider et al.
EUROPEAN JOURNAL OF CANCER (2006)
Familial risks and temporal incidence trends of multiple myeloma
Andrea Altieri et al.
EUROPEAN JOURNAL OF CANCER (2006)
Myeloma - new approaches to combined nephrological-haematological management
M Haubitz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
K Dredge et al.
MICROVASCULAR RESEARCH (2005)
Properties of thalidomide and its analogues: Implications for anticancer therapy
SK Teo
AAPS JOURNAL (2005)
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
K Dredge et al.
BRITISH JOURNAL OF CANCER (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Share Paper
